India bladder cancer market is estimated to grow modestly at a CAGR of around 9.9% during the forecast period. The market growth attribited to the prevalence of smoking among adults and elders, various type of cancer is being diagnosed in the country. With the increasing population affected by smoking, bladder cancer cases are estimated to grow multi-fold in the country. The number of bladder cancer patients is directly proportional to the increasing population of the country, which as a result is supposed to augment the growth of the bladder cancer market in India during the forecast period.
India is one of the fastest emerging economies across the globe and with the growth in the economy, the healthcare sector is developing with a considerable rate in the country. The increasing number of diseases is one of the major factors contributing to the development of the healthcare system of the country. According to IBEF (India Brand Equity Foundation), India’s healthcare industry has reached $160 billion in 2017 and is estimated to grow at the CAGR of 16.3% till 2022. The industry is estimated to reach $372 billion in 2022. With the growing healthcare industry of the country, the bladder cancer market in the country is estimated to increase with a significant rate during the forecast period.
India bladder cancer market is segmented into cancer type, diagnosis, and treatment. Based on cancer type, the market is segmented into transitional cell bladder cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and other rare types (sarcomas, carcinoma in situ). Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy.
The companies which are contributing to the growth of the India bladder cancer market include AstraZeneca PLC, Bristol-Myers Squibb, Co., Eli Lilly & Co., GlaxoSmithKline PLC, and Pfizer, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.
Research Methodology
The market study of the India bladder cancer market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include
The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.
Market Segmentation
The Report Covers
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. India Bladder Cancer Market by Cancer Type
5.1.1. Transitional Cell Bladder Cancer/ Urothelial Carcinoma
5.1.2. Squamous Cell Bladder Cancer
5.1.3. Adenocarcinoma
5.1.4. Others (Sarcomas, Carcinoma in Situ)
5.2. India Bladder Cancer Market by Diagnosis
5.2.1. Cystoscopy
5.2.2. Biopsy
5.2.3. Urinalysis
5.2.4. Urine Cytology
5.2.5. Intravenous Pyelogram (IVP)
5.2.6. Others (Biomarkers)
5.3. India Bladder Cancer Market by Treatment
5.3.1. Surgery
5.3.2. Chemotherapy
5.3.3. Immunotherapy
5.3.4. Radiation Therapy
5.3.5. Others (Targeted Therapy)
6. Company Profiles
6.1. Astellas Pharma Inc.
6.2. AstraZeneca PLC
6.3. Bayer AG
6.4. Bristol-Myers Squibb Co.
6.5. Eli Lilly and Co.
6.6. F. Hoffmann-La Roche AG
6.7. GlaxoSmithKline Plc
6.8. Johnson & Johnson Services, Inc.
6.9. Merck KGaA
6.10. Pfizer Inc.
6.11. Sysmex Corp.
1. INDIA BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2019-2026 ($ MILLION)
2. INDIA BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2019-2026 ($ MILLION)
3. INDIA BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
1. INDIA BLADDER CANCER MARKET SHARE BY CANCER TYPE, 2019 VS 2026 (%)
2. INDIA BLADDER CANCER MARKET SHARE BY DIAGNOSIS, 2019 VS 2026 (%)
3. INDIA BLADDER CANCER MARKET SHARE BY TREATMENT, 2019 VS 2026 (%)